康方生物(09926.HK) 今日(28日)低开14.96%,最低见84.1元。现报84.1元,跌14.96%,成交125.4万股,涉资1.05亿元。公司公布,公司自主研发的全球首创双特异性抗体依达方(依沃西,PD-1/VEGF)单药用于PD-L1阳性的表皮生长因子受体(EGFR)基因突变阴性和间变性淋巴瘤激酶(ALK)阴性的局部晚期或转移性非小细胞肺癌(NSCLC)的一线治疗的新药上市申请(...
Source Link康方生物(09926.HK) 今日(28日)低开14.96%,最低见84.1元。现报84.1元,跌14.96%,成交125.4万股,涉资1.05亿元。公司公布,公司自主研发的全球首创双特异性抗体依达方(依沃西,PD-1/VEGF)单药用于PD-L1阳性的表皮生长因子受体(EGFR)基因突变阴性和间变性淋巴瘤激酶(ALK)阴性的局部晚期或转移性非小细胞肺癌(NSCLC)的一线治疗的新药上市申请(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.